Is BPC-157 safe for dogs?
The short answer
BPC-157 has the most reassuring safety record of any compound on this site as it applies to dogs. A dedicated preclinical safety evaluation identified no lethal dose, no genotoxicity, and no teratogenicity, and the canine pharmacokinetic study reported good tolerance across seven days of repeated dosing at 30 mcg/kg — several times a typical clinical dose. The meaningful caveat is duration rather than dose: long-term continuous use in dogs has not been studied.
Additional cautions
Limited long-term canine data
The published canine work covers short-duration dosing. Multi-month continuous administration in dogs has not been formally studied, so extended use should be a deliberate decision made with your veterinarian rather than a default.
What the evidence base actually is
Safety claims are only as good as the studies behind them.
BPC-157 is a short chain of fifteen amino acids originally identified in gastric juice. Research describes it encouraging the growth of new blood vessels into damaged tissue, which is the rate-limiting step in most healing. Studies also report a protective effect on the lining of the gut. It is the one compound here with a published pharmacokinetic study performed in dogs, which is why it appears first on almost every canine protocol.
Dosing context
Safety is dose-dependent. These are the figures reported in the source literature.
| Weight class | Reported dose | Frequency | Duration | Studied for |
|---|---|---|---|---|
| Small / toy breedunder 22 lb (10 kg) | 20-100 mcg per day | Once daily | 2-4 weeks | Gastrointestinal issues, joint injury, post-surgical recovery |
| Medium breed22–77 lb (10–35 kg) | 50-250 mcg per day | Once daily | 2-8 weeks | Tendon and ligament injury, gut protection, wound healing |
| Large / giant breedover 77 lb (35 kg) | 100-500 mcg per day | Once daily | 2-8 weeks | Orthopaedic recovery, chronic degenerative conditions |
See the full BPC-157 profile for mechanism, protocol and monitoring detail.
Common questions
Is BPC-157 safe for dogs?+
BPC-157 has the most reassuring safety record of any compound on this site as it applies to dogs. A dedicated preclinical safety evaluation identified no lethal dose, no genotoxicity, and no teratogenicity, and the canine pharmacokinetic study reported good tolerance across seven days of repeated dosing at 30 mcg/kg — several times a typical clinical dose. The meaningful caveat is duration rather than dose: long-term continuous use in dogs has not been studied.
What are the side effects of BPC-157 in dogs?+
Limited long-term canine data: The published canine work covers short-duration dosing. Multi-month continuous administration in dogs has not been formally studied, so extended use should be a deliberate decision made with your veterinarian rather than a default.
Can BPC-157 be given to a dog with cancer?+
No cancer-specific contraindication is established for BPC-157 in the published literature. Any dog with a diagnosed malignancy should nevertheless have its full protocol reviewed by the veterinarian managing the case, since interactions with active treatment are not well characterised.
Does my dog need testing before starting BPC-157?+
No compound-specific genetic testing is established for BPC-157. Baseline bloodwork before starting, and repeat testing during a protocol, is standard practice and lets your veterinarian catch a problem before it becomes clinically apparent.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.